| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-02-17 |
| タイトル |
|
|
タイトル |
Prognosis of patients with bronchiectasis receiving long-term oxygen therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Bronchiectasis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Chronic obstructive pulmonary disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hypoxemia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Interstitial lung disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Long-term oxygen therapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Nontuberculous mycobacteria |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ono, Kazuki
Ito, Masashi
Harada, Risako
Ohe, Takashi
Furuuchi, Koji
Fujiwara, Keiji
Kodama, Tatsuya
Tabusadani, Mitsuru
Morimoto, Kozo
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives: Long-term oxygen therapy (LTOT) for bronchiectasis is recommended using the same eligibility criteria as for chronic obstructive pulmonary disease (COPD); however, the evidence supporting LTOT in bronchiectasis is limited, and no studies have evaluated the prognosis of the disease in these patients. The aim of the present study was to investigate the characteristics and prognosis of bronchiectasis in patients receiving LTOT. Methods: This retrospective cohort study included patients with bronchiectasis and COPD who started LTOT between April 2011 and September 2022. Patients with interstitial lung disease (ILD) who started LTOT after June 2020 while receiving antifibrotic therapy were also included. We compared baseline characteristics and survival times among patients with bronchiectasis, COPD, and ILD. Furthermore, among patients with bronchiectasis, we compared these parameters between those with nontuberculous mycobacteria (NTM) culture-positive and NTM culture-negative results. Results: A total of 93 consecutive patients with bronchiectasis were newly initiated on LTOT. Compared with patients with COPD and ILD, those with bronchiectasis had a significantly lower BMI, %FVC and %FEV. Survival was significantly shorter in patients with bronchiectasis (664 [372–1078] days) than in those with COPD (1008 [590–1722] days), whereas no significant difference was observed compared to ILD (669 [208–989] days). Patients who were NTM culture-positive (405 [156–646] days) had a significantly shorter survival than those who were NTM culture-negative (946 [573–1380] days). Conclusions: The prognosis of bronchiectasis in patients was extremely poor, worse than that of COPD and comparable to that of ILD. |
|
言語 |
en |
| 書誌情報 |
en : Respiratory Medicine
巻 252,
p. art. no. 108655,
発行日 2026-01-19
|
| 出版者 |
|
|
出版者 |
Elsevier Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
09546111 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.rmed.2026.108655 |
| 権利 |
|
|
権利情報 |
© 2026 Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Respiratory medicine, 252, art. no. 108655; 2026 |
|
言語 |
en |
RM252_108655.pdf (521 KB)
